MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Home・Elenco Azioni・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

88.13 1.44

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

86.42

Massimo

89.56

Metriche Chiave
By Trading Economics
Entrata	5.4M -48M
Vendite	6M 57M
Margine di Profitto	-82.974
Dipendenti	414
EBITDA	5.1M -43M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+76.97% upside

Dividendi
By Dow Jones
Utili prossimi	6 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-1.2B 5.3B
Apertura precedente	86.69
Chiusura precedente	88.13

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

60 / 65.58 Supporto e resistenza

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 apr 2026, 22:56 UTC

Principali Notizie su Eventi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 apr 2026, 20:50 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 apr 2026, 23:55 UTC

Discorsi di Mercato

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 apr 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 apr 2026, 23:23 UTC

Principali Notizie su Eventi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 apr 2026, 23:07 UTC

Utili

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 apr 2026, 23:02 UTC

Principali Notizie su Eventi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 apr 2026, 23:00 UTC

Principali Notizie su Eventi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 apr 2026, 22:39 UTC

Utili

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 apr 2026, 22:08 UTC

Discorsi di Mercato

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 apr 2026, 22:00 UTC

Principali Notizie su Eventi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 apr 2026, 21:56 UTC

Acquisizioni, Fusioni, Takeovers

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 apr 2026, 21:31 UTC

Principali Notizie su Eventi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

1 apr 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

1 apr 2026, 20:38 UTC

Utili

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 apr 2026, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 apr 2026, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 apr 2026, 20:16 UTC

Acquisizioni, Fusioni, Takeovers

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 apr 2026, 20:13 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 apr 2026, 20:07 UTC

Discorsi di Mercato

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 apr 2026, 20:07 UTC

Acquisizioni, Fusioni, Takeovers

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

76.97% in crescita

Previsioni per 12 mesi

Media 136.71 USD 76.97%

Alto 158 USD

Basso 105 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

60 / 65.58Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.